Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Methadone Maintenance Treatment Patients in China: a Randomized Controlled Trial
Sponsor: Centers for Disease Control and Prevention, China
Listed as NCT02991599, this PHASE4 trial focuses on Hepatitis B Vaccine and remains completed. Sponsored by Centers for Disease Control and Prevention, China, it has been updated 8 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
▶ Show 3 earlier versions
-
Aug 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Dec 2018 — Aug 2019 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Dec 2018 [monthly]
Active Not Recruiting PHASE4
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centers for Disease Control and Prevention, China
- Shanxi Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.